Maximum Views Reached

You have reached the maximum number of Guideline views for today. By creating a free account, you can increase your number of complimentary daily views.

To view this Guideline, please log in to your account. If you do not have an account, you can create one for free by clicking the button below.

Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer

Publication Date: April 19, 2022

Last Updated: April 19, 2022

Diagnosis

Newly Diagnosed ER-positive, HER2-negative Breast Cancer

Oncotype DX (21-gene recurrence score)

Recommendation 1.1

If a patient has node-negative breast cancer, the clinician may use Oncotype DX test to guide decisions for adjuvant endocrine and chemotherapy. ( EB , H , S )

614

Overview

Title

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer